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There has been an increasing recognition that mitochondrial perturbations play a central role in 
human heart failure. Discovery of mitochondrial networks, whose function is to maintain the 
regulation of mitochondrial biogenesis, autophagy (‘mitophagy’) and mitochondrial fusion/fission, 
are new potential therapeutic targets. Yet our understanding of how the molecular underpinning of 
these processes is just emerging. We recently identified a role of the SWI/SNF ATP-dependent 
chromatin remodeling complexes in the metabolic homeostasis of the adult cardiomyocyte using 
cardiomyocyte-specific and inducible deletion of the SWI/SNF ATPases BRG1 and BRM in adult 
mice (Brg1/Brm double mutant mice). To build upon these observations in early alterated 
metabolism, the present study looks at the subsequent alterations in mitochondrial quality control 
mechanisms in the impaired adult cardiomyocyte. We identified that Brg1/Brm double-mutant 
mice exhibited an increased mitochondrial biogenesis, increases in ‘mitophagy’, and alterations in 
mitochondrial fission and fusion that led to small, fragmented mitochondria. Mechanistically, 
increases in the autophagy and mitophagy-regulated proteins Beclin1 and Bnip3 were identified, 
paralleling changes seen in human heart failure. Cardiac mitochondrial dynamics were perturbed 
including decreased mitochondria size, reduced number, and altered expression of genes 
regulating fusion (Mfn1, Opa1) and fission (Drp1). We also identified cardiac protein amyloid 
accumulation (aggregated fibrils) during disease progression along with an increase in pre-amyloid 
oligomers and an upregulated unfolded protein response including increased GRP78, CHOP, and 
IRE-1 signaling. Together, these findings described a role for BRG1 and BRM in mitochondrial 
quality control, by regulating mitochondrial number, mitophagy, and mitochondrial dynamics not 
previously recognized in the adult cardiomyocyte. As epigenetic mechanisms are critical to the 
pathogenesis of heart failure, these novel pathways identified indicate that SWI/SNF chromatin 
remodeling functions are closely linked to mitochondrial quality control mechanisms.
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Introduction
As heart failure treatment has evolved, increasing recognition mitochondria’s role in the 
pathogenesis of disease has emerged1. New techniques allow the discovery of mitochondrial 
networks, whose function is maintained by three processes, including 1) mitochondrial 
biogenesis (increase in mitochondrial number); 2) mitophagy; and 3) continuous 
mitochondrial fission (division) and fusion2, 3. Impaired mitochondrial biogenesis is a 
feature of myocardial hypertrophy and end-stage ischemic heart failure in humans4, while 
autophagy has been central to defects in human heart failure5, 6. Evidence of altered 
mitochondrial dynamics (fission and fusion) in human heart failure, specifically in idiopathic 
dilated cardiomyopathy, has recently been reported7.
Changes in the mitochondrial network influence the production of ROS and ATP production, 
most notably offset by activating mitochondrial biogenesis and mitophagy in exercise and 
other therapeutic modalities. Complementing mitochondrial biogenesis is the ongoing 
process of “mitophagy” (mitochondrial autophagy), where damaged/dysfunctional 
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mitochondria are targeted for destruction via lysosomal degradation. Here mitochondrial 
proteins such as BNIP3L and BNIP3 are abundant in the heart and act as targeting molecules 
that attract autophagosome to mitochondria and are critical to maintaining cardiac function3. 
Lastly, regulation of mitochondrial dynamics (fission and fusion) involve the redistribution 
of mitochondrial content8. With the enormous continuous ATP demand of the 
cardiomyocyte, the importance of maintaining mitochondrial quality control is of particular 
significance in cardiac disease, including heart failure, ischemic heart disease/myocardial 
infarction, and diabetes9–11.
Epigenetic regulation of heart failure occurs by several key mechanisms, including ATP-
dependent chromatin remodeling12. One ATP-dependent chromatin remodeling complex in 
cardiomyocytes are the SWI/SNF (SWItch/Sucrose Non-Fermentable) complexes, 
comprised of 9–12 subunits, including one of two ATPases critical to their function 1) BRG1 
(Brahma-related gene 1) or 2) BRM (Brahma)13, 14. Recent studies demonstrate a role of 
BRG1 and BRM in maintaining homeostasis in the adult cardiomyocyte. These studies 
identified that cardiomyocyte-specific and inducible deletion of BRG1 and BRM in adult 
mice (Brg1/Brm double mutant mice), alterations in glucose-6-phosphate, fructose-6-
phosphate, and myoinositol at day 10 post-induction occurred before severe cardiomyopathy 
is seen15. The identification of these early metabolic changes led to the current study to 
identify the underlying mechanisms by which BRG1 and BRM deletion affect mitochondrial 
quality control mechanisms in the impaired adult cardiomyocyte.
In the present study, we build upon our findings that Brg1/Brm double mutant hearts have 
early metabolic changes at day ten (10) by investigating the changes occurring 15 days after 
inducing Brg1 deletion, just before the development of a severe cardiomyopathy. We 
identified alterations in mitochondrial biogenesis, mitochondrial autophagy (mitophagy), 
and mitochondrial fission and fusion just before the death that occurred in all mice by day 
22. We demonstrate a previously undescribed link between the chromatin remodeling 
SWI/SNF components BRG1 and BRM with mitochondrial homeostasis. On a more 
practical note, the present study should give those develop BRG1 and BRM inhibitors for 
cancer pause16.
Methods
Animal creation and experimental design
All mouse experiments were approved by the Institutional Animal Care and Use Committees 
(IACUC) review board at the University of North Carolina at Chapel Hill. The αMHC-Cre-
ERT mice were obtained from The Jackson Laboratory (#005657, Bar Harbor, ME); the 
Brg1 conditional mutant mouse line and Brm constitutive mutant mouse line have been 
described previously17–19. Genotyping of the αMHC-MerCreMer, Brg1 floxed, and Δfloxed 
alleles and the Brm mutation were genotyped by PCR as previously described17–20.
Histology, transmission electron microscopy (TEM), and image analysis
Immunohistochemistry (IHC) was performed on fixed histological section using an anti-
BRG1 rabbit polyclonal antibody (Millipore #07-478, Temecula, CA), anti-GRP78 mouse 
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monoclonal antibody21, anti-CHOP (GADD153), or phospho-eIF2, as previously 
described22, 23. Hearts analyzed by TEM were viewed on a LEO EM910 transmission 
electron microscope operating at 80 kV (LEO Electron Microscopy, Thornwood, NY). An 
average of 2,500 mitochondria were analyzed from 30 fields from multiple levels from three 
hearts per mouse cohort.
Analysis of autophagic flux in vivo
Autophagic flux was determined in vivo from the titration of bafilomycin A1 as previously 
described24. Antibodies for LC3B isoforms (Sigma-Aldrich #L7543) and beclin were used 
for western immunoblot analysis of markers of autophagy (Cell Signaling #3495P, Beverly, 
MA).
Quantitative analysis of cardiac amyloid (protein aggregation) and pre-amyloid oligomers 
(PAOs)
Protein aggregation was assessed using an Enzo Proteostat Protein Aggregation Assay 
(#ENZ-51023, Farmingdale, NY) in conjunction with their pre-formulated aggregation 
standards (#ENZ-51039) and pre-amyloid oligomer staining was performed as described in 
detail25.
RNA isolation and RT-qPCR analysis
Total RNA was isolated from cardiac tissue homogenized with a TissueLyser LT (Qiagen 
N.V. #69980, Venlo, The Netherlands) using
Trizol (Life Technologies #15596-026, Carlsbad, CA) according to the manufacturer’s 
instructions. TaqMan gene expression assays (Life Technologies) were performed using 
universal TaqMan master mix (Life Technologies #4304437) commercial probes, as 
described previously24.
Analysis of mitochondrial DNA by qPCR
Mitochondrial number was quantified by qPCR on DNA prepared from whole-heart 
homogenates using the DNAeasy Blood and Tissue Kit (Qiagen #69506). SYBR Green and 
primers for the mitochondrial DNA included mtNd1, mtCO1, and mtCytb1; H19 was run in 
parallel as a nuclear DNA control as previously detailed26.
Statistics
SigmaPlot (Systat Software, Inc., San Jose, CA) was used to determine significant statistical 
difference by One-way ANOVA followed by post-hoc analysis using the Holm–Sidak 
method or a Student’s t-test, as indicated. A p value < 0.05 was considered significant.
Additional materials and methods detail may be found in the online supplement.
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Results
A Mouse Model Reveals SWI/SNF Complexes are Essential in Adult Cardiomyocytes
To investigate the combined role of BRG1 and BRM in adult cardiomyocytes, we crossed 
mice carrying an inducible, cardiomyocyte-specific αMHC-Cre-ERT transgene to Brg1fl/fl; 
Brm−/−mice. Adult Brg1fl/fl; αMHC-Cre-ERT+/0; Brm−/− mice were then fed tamoxifen-
fortified chow for 7 days to induce the Brg1 floxed-to-Δfloxed excision event, which was 
confirmed by both PCR and IHC (Supplemental Fig. 1A, B). These mice (herein referred to 
as Brg1/Brm double mutants) were monitored by echocardiography until they died, which 
occurred within 22 days of initiating the tamoxifen diet (Supplemental Fig. 1C). A 
progressive heart failure occurred prior to death in Brg1/Brm double-mutant but not in 
control mice (Table 1). Six groups of control mice were analyzed in parallel (listed in 
Supplemental Fig. 1C) to ensure that we were observing a Brg1/Brm double-mutant 
phenotype rather than an artifact, such as tamoxifen itself or tamoxifen-induced Cre 
dysfunction, which has been previously described27.
Brg1/Brm Double-Mutant Cardiomyocytes Undergo Mitophagy and Altered Mitochondrial 
Dynamics
Considering the severity of the cardiac phenotype and the rapid lethality of mice lacking 
Brg1 and Brm in their cardiomyocytes, the histopathology was surprisingly mild. Analysis 
of H&E-and Mason’s Trichrome-stained sections revealed that the Brg1/Brm double-mutant 
phenotype ranged from relatively normal to moderate vacuolization (Fig. 1A) with no 
evidence of lipid accumulation by oil red O staining (Supplemental Fig. 2) and with fibrosis 
increased only in rare individuals (Fig. 1B, Supplemental Fig. 3). Next, we assessed fetal 
cardiomyocyte gene expression because it is a typical pathological hypertrophic response 
that occurs during heart failure. Skeletal muscle actin was significantly decreased at both 
time points in the Brg1/Brm double-mutant hearts compared with controls (Fig. 1C). βMHC 
fetal gene expression was significantly elevated at day 10 post-tamoxifen induction (early 
time point) but not at 1-day pre-mortem (late time point) (Fig. 1C and 1D). In contrast, Bnp 
and Anf mRNA were not changed significantly at either time point. These data are not 
representative of a typical pathologic hypertrophy/heart failure response.
Ultrastructural analysis of the Brg1/Brm double-mutant heart by TEM was distinct by the 
presence of alterations limited to the interfibrillar areas (mitochondrial compartment). In all 
of the Brg1/Brm double-mutant hearts, we identified mitochondria degeneration (Fig. 2A 
and 2B) and an increase in double-membrane bound vacuoles with mitochondrial remnants 
within (Fig. 2B) that were absent in all of the parallel control hearts (Fig. 2C). 
Ultrastructurally, these vacuoles appeared similar to those found to be increased in the 
process of autophagy, specifically autophagosomes. Autophagy is a lysosomal degradation 
pathway for cytoplasmic material and organelles, starting at the endoplasmic reticulum-
mitochondria interface28. The conserved autophagic process shuttles cytoplasmic 
components to fuse with lysosomes. This stepwise engulfment of cytoplasmic material by 
the phagophore, maturing into a double-membrane-bound vesicle, forms the 
autophagosome. To confirm that Brg1/Brm double-mutant hearts had quantitative alterations 
in autophagy, we next analyzed autophagic flux in vivo.
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The role of autophagy in cardiovascular biology has proven to be context dependent, widely 
characterized in cardiomyocytes, and critical to the maintenance of cardiovascular 
homeostasis and function29. Depending on context, there is a window of optimal autophagic 
activity, whereby increases or decreases may be protective depending upon the cardiac stress 
disease state30, 31. Brg1/Brm double-mutant hearts exhibited a significant increase in 
autophagic flux, as illustrated by the LC3II:LC3I ratio by western immunoblot after 
bafilomycin A1 treatment, compared with control mice run in parallel (Fig. 3A). In parallel 
with this evidence of increased autaphagic flux, we identified increased Beclin 1 by western 
immunoblot analysis (Fig. 3B). With evidence of increased autophagy, we next investigated 
mechanisms responsible for upregulating autophagy.
Central to the regulation of autophagy in heart disease, the Beclin 1 protein functions as a 
scaffolding protein assembling Beclin 1 interactome to regulate Class II PI3K/VPS34 
activity, which tightly controls autophagy at multiple stages32. The Brg1/Brm double-mutant 
mice had significantly increased Beclin 1 protein expression compared with control group 
mice (Fig. 3B). Autophagy is also regulated at the transcriptional level, with increased Atg5, 
Atg7, Atg12, Bnip3, and Vps34 mRNA to enhance autophagy33. RT-qPCR analysis of these 
genes demonstrated the Brg1/Brm double-mutant hearts had a significant increase in Bnip3 
mRNA levels, while Atg12 and Vps34 were significantly decreased compared with control 
hearts at day 15 (Fig. 3C). At the earlier day 9 time point, Brg1/Brm double-mutant hearts 
had increased Vps34 mRNA and decreased Bnip3 mRNA (Supplemental Fig. 4), illustrating 
the dynamic expression of autophagy regulators. The transcriptional and epigenetic network 
regulating autophagy is emerging (as recently reviewed33) that underscore the diverse ways 
in which autophagy can be regulated depending on the stimulus. To test whether BRG1 and 
BRM occupy the Bnip3 promoter, we performed quantitative ChIP assays. Significant 
enrichment of BRG1 and BRM was detected in cardiac tissue (Fig. 3D), which strongly 
suggests that BRG1- and BRM-catalyzed SWI/SNF complexes directly regulate Bnip3. 
BNIP3, primarily located in the mitochondria as an integrated protein34, perturbs outer 
membrane integrity35, induces permeabilization of the inner mitochondrial membrane36, and 
can stimulate mitophagy directly by triggering depolarization and Parkin recruitment37. 
Taken together, these findings illustrate a novel role for BRG1 and BRM in the maintenance 
of cardiomyocyte autophagic flux, specifically related to the mitophagy as illustrated by the 
TEM analysis and the direct regulation of Bnip3.
BNIP3 alters cellular mitochondrial dynamics, a continuous process by which mitochondria 
fuse together (fusion) and subsequently divide (fission) to maintain their functional 
balance38. Specifically, increasing BNIP3 expression can induce mitochondrial 
fragmentation (fission) in cells34, 39. Understanding this link led us to evaluate further the 
Brg1/Brm double-mutant heart mitochondrial phenotype in our TEM studies. Here TEM 
revealed an apparent increase in Brg1/Brm double-mutant heart mitochondrial fragmentation 
compared with controls (Fig. 4A). Analysis of mitochondria over multiple LV regions 
revealed that the number of small mitochondria identified in the Brg1/Brm double-mutant 
hearts was skewed with a marked increase in small mitochondria with significantly smaller 
areas (Fig. 4B and 4C). To put in context the apparent increase in small mitochondria, we 
determined mitochondrial number by qPCR of three mitochondrial encoded genes 
normalized to the nuclear-encoded H19 and found a significant decrease in the number of 
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mitochondria (Fig. 5A). The fusion and fission of mitochondria is a dynamic process that 
cells use for responding to mitophagy and maintaining protein quality. The regulation of 
mitochondrial dynamics by fusion and fission is regulated by four dynamin-related GTPases, 
including DRP1 and FIS1 (fission)40, 41 and mitofusins (e.g. MFN1) in the outer membrane 
and OPA1 in the inner membrane (fusion)42, 43. RT-qPCR analysis of these GTPases in the 
Brg1/Brm double-mutant hearts demonstrated significant decreases in Mfn1, Opa1, and 
Drp1 in late disease (Fig. 5B and 5C) but not at an earlier stage (Supplemental Fig. 5). These 
findings demonstrate the interesting juxtaposition of increased mitophagy and mitochondrial 
fission, which has been shown to allow the selective elimination of damaged mitochondria 
by autophagy44, 45
Activation of the UPR in Brg1/Brm Double-Mutant Cardiomyocytes
Histological analysis of the Brg1/Brm double-mutant hearts stained with H&E revealed 
stereotypical pink accumulation inside of the cardiomyocytes, resembling the unfolded 
proteins that accumulate in cardiac amyloidosis (Supplemental Fig. 3E). Since the 
accumulation of unfolded proteins in mitochondria has been shown to induce mitophagy in 
neurons46, we next investigated the presence of unfolded proteins using a colorimetric assay 
that has been used to identify amyloid and other unfolded proteins in experimental disease 
processes47–51. At an early time point, Brg1/Brm double-mutant hearts did not have an 
increase in unfolded proteins (Fig. 6A, left). However, at later time points when mitophagy 
and altered fission and fusion were present (Figs. 2–5), a significant increase in unfolded 
proteins was present with a ~3-fold increase compared with control hearts (Fig. 6A, right). 
The pathogenic effects of the accumulation of amyloid fibrils, independent of soluble 
precursors, have been described in the heart52. Recent studies have identified a critical role 
of pre-amyloid oligomers (PAOs) that form before amyloid/insoluble fibrils in mediating 
heart failure directly, paralleling the pathogenesis of common neurodegenerative diseases, 
including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease53.
Using the A11 antibody, we investigated the presence of PAOs in early and late Brg1/Brm 
double-mutant heart samples (Fig. 6B). The detection of low levels of PAO by the A11 
antibody (green) present in cardiomyocytes (red) detected by an antibody against the heavy 
chain myosin II using immunofluorescence indicates that soluble PAOs were increasing at 
day 15 in Brg1/Brm double-mutant hearts (Fig. 6B). While not reaching significant levels, 
these findings suggest that the protein aggregates detected in the heart at day 15 (Fig. 6A) go 
through a PAO state very quickly to accumulate amyloid in significant amounts when Brg1 
and Brm have been ablated in adult cardiomyocyte in vivo.
In response to stress, such as that induced by oxidized proteins, the heart induces the 
unfolded protein response (UPR), which includes the endoplasmic reticulum (ER) chaperone 
protein GRP7854. GRP78 is found in the endoplasmic/sarcoplasmic reticulum bound to 
PERK, IRE1, and ATF6 receptors to prevent their activation of the UPR55. In the presence 
of unfolded proteins, GRP78 preferentially shifts to these proteins to stabilize their 
confirmation, leaving PERK, IRE1, and ATF6 to signal survival and apoptotic signaling 
downstream55. Having established the presence of increased amyloid in these hearts, we 
next investigated cardiac expression of GRP78 by IHC and identified that Brg1/Brm double-
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mutant mice had markedly increased GRP78 expression compared with controls (Fig. 7A) at 
the late time point where PAOs and amyloid were increased.
The link between the UPR and cardiovascular disease is strengthening56, but UPRs are 
diverse and include signaling by IRE-1, PERK, and ATF657, 58. Identification of the spliced 
Xbp-1 by RT-qPCR is one way in which IRE-1 activity is measured58. We identified that 
Brg1/Brm double-mutant hearts had a significant increase in the spliced Xbp-1 mRNA 
compared with control hearts (Fig. 7B). Downstream of the IRE1-XBP-1 pathway, XBP1 
binds the promoter of the C/EBPα (Cebpa) gene to increase its expression59. Brg1/Brm 
double-mutant mice had significantly more Cebpa mRNA expression compared with 
controls (Fig. 7B). The significant increase in Brg1/Brm double-mutant heart Xbp-1 splice 
variant mRNA and Cebpa mRNA demonstrate the increased activity via IRE-1 signaling. 
The relationship between XBP1 and C/EBPβ (Cebpb) is a bit more complex, with evidence 
that C/EBPβ induces expression of XBP1 protein59. Brg1/Brm double-mutant hearts had 
diminished Cebpb mRNA levels that were not significant (Fig. 7B).
The stress caused in the ER by the presence of unfolded proteins can also cause signaling 
through PERK, whereby PERK proteins dimerize and undergo autophosphorylation60. This 
autophosphorylation leads to downstream phosphorylation of eIF2, which we investigated 
by IHC (Fig. 7A, column 2). Here we found evidence that the Brg1/Brm double-mutant 
mice had a higher cardiac eIF2 expression histologically, and next looked at downstream 
ATF4 and CHOP expression by RT qPCR55. Significant increases in both Chop and Atf3 
mRNA were identified by RT qPCR in the Brg1/Brm double-mutant mice (Fig. 7B), with 
increases in CHOP protein also seen by IHC in the Brg1/Brm double-mutant mice (Fig. 7A, 
column 3). Activation of ATF4 increases target gene expression, including the transcription 
factor CHOP (CCAAT/-enhancer-binding protein homologous protein)61, which itself 
induces the expression of Atf3 mRNA62. While the lack of reliable reagents prevented us 
from directly measuring ATF6 signaling61, we determined the mRNA levels of other 
reported genes involved in the UPR. We found that Brg1/Brm double-mutant hearts had 
either significant down-regulation of Ire-1a, Atf6a, and Grp78 reflecting compensatory 
responses to the clear GRP78 and IRE-1 signaling present, or no change in genes not as 
clearly related to the UPR in cardiomyocytes61 (Supplemental Fig. 6).
Discussion
This study identifies a novel role of the SWI/SNF components BRG1 and BRM in the 
homeostasis of the adult cardiomyocyte regulating mitochondrial biogenesis, mitophagy, and 
mitochondrial fission and fusion. While there have been suggestions that SWI/SNF 
complexes may be related to mitochondrial biogenesis63 and autophagy64 in mammalian 
cells, the present study is the first to link them additionally to mitochondrial fission and 
fusion. While these findings parallel changes seen in heart failure phenotypes, BRG1 and 
BRM have previously been shown to have a role in the development of pathological cardiac 
hypertrophy. BRG1 interactions with the DNA-binding protein PARP1 have been implicated 
in the prototypical shift in cardiac MHC isoform expression in pathological cardiac 
hypertrophy65, and may explain the decreases (instead of increases) of βMHC seen with the 
heart failure in the present study (Fig. 1B). In the present study, we describe the redundant 
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role of BRG1 and BRM to maintain the adult cardiomyocyte in vivo. Notably, multiple 
distinct alterations have been identified in this model, with early metabolomics changes 
previously identified15, accompanying the upregulation of autophagy/mitophagy, altered 
mitochondrial dynamics, accumulation of PAOs/aggregated protein, and activation of the 
UPR that culminated in severe bradycardia and death (reported here).
The increased autophagic flux present in Brg1/Brm double-mutant hearts was characterized 
morphologically by increases in mitochondria in what look like autophagosomes (Fig. 2) 
and by increased Beclin 1 protein and Bnip3 mRNA (Fig. 3). While the process of 
autophagy has largely been described in terms of transcriptional regulation, the epigenetic 
control of autophagic flux is gaining ground33. Multiple transcription factors and epigenetic 
regulators have been shown to be involved33. We demonstrate that BRG1 and BRM occupy 
the Bnip3 promoter and regulate its expression as well as autophagic flux. The 
transcriptional activation of Bnip3, as seen in the Brg1/Brm double-mutant hearts, has been 
reported to be by C/EBPβ, E2F1, FOXO1/3, HIF1, and STAT333. The enhanced Beclin 1, 
also seen in the Brg1/Brm double-mutant hearts, has been reported to be regulated by 
FOXO1/3, NF-κB, p63, and Stat33. BNIP3 is a receptor, like PINK1 and Parkin, regulates 
mitochondrial autophagy (also known as mitophagy)66, 67, consistent with the morphological 
findings in Brg1/Brm double-mutant hearts. Increases in BNIP3 expression occur after 
myocardial infarction and in response to chronic pressure overload hypertrophy and may be 
a mechanism by which mitochondrial pruning is mediated to get rid of damaged 
mitochondria during increased stress68. BRG1 and BRM may be linked to the regulation of 
HIF1, as the SWI/SNF complex regulates HIF-1-dependent mitophagy (regulated through 
BNIP3 and Beclin1) as a metabolic adaptation to stress in cancer cells69, 70.
The regulation of mitochondrial autophagy and mitochondrial dynamics is logically linked 
to mitochondrial quality control. Mitochondria are damaged by many environmental 
stressors, and repair is dependent upon the mitochondrial fission and fusion (broadly known 
as mitochondrial dynamics) and autophagy71. In fact, mitochondrial fusion and fission are 
processes essential for the preservation of normal mitochondrial function. In heart failure, 
OPA1 is important for maintaining normal cristae structure and function, while preserving 
the inner membrane structure and for protection against apoptosis. Confocal and TEM 
analysis have demonstrated that failing hearts have small, fragmented mitochondria, 
consistent with decreased fusion. Reducing OPA1 or MFN1 in cardiomyocytes results in 
increased mitochondrial fragmentation72, 73. The transcriptional regulation of genes involved 
with mitochondrial fusion in cardiomyocytes (i.e. OPA1 and MFN1) as well as fission (e.g. 
DRP1) has been recently shown to be under the control of PGC-1α by coactivating the 
estrogen-related receptor α74. While the SWI/SNF complex component BAF60a supports 
PGC-1α co-activation63, the regulation of mitochondrial fission by Brg1/Brm demonstrated 
here has not been described previously.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Non-standard abbreviations
AL light chain
ANF atrial natriuretic factor
βMHC beta myosin heavy chain
BNP brain natriuretic peptide
BRM Brahma (aka SMARCA2)
BRG1 Brahma-related gene 1 (aka SMARCA4)
CHOP CCAAT/-enhancer-binding protein homologous protein
ER endoplasmic reticulum
HDAC histone deacetylase
HF heart failure
PAO pre-amyloid oligomer
SWI/SNF SWItch/Sucrose Non-Fermentable
TAC Trans-aortic constriction
TEM transmission electron microscopy
UPR unfolded protein response
VEC vascular endothelial cells
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Fig. 1. 
Cardiomyocyte vacuolization and induction of αMHC in Brg1/Brm double-mutant hearts. 
A. Representative H&E- and Mason’s Trichrome-stained heart sections from Brg1/Brm 
double-mutant and control mice as indicated. B. Quantitative analysis of fibrosis in 
Brg1/Brm double-mutant hearts by logarithmic non-biased analysis of collagen (N=3 per 
group). C. RT-qPCR analysis of fetal genes that are induced during cardiac hypertrophy at 
early (N=3 per control Group 3, 7 per Brg1/Brm Double Mutant group 4) and D. late time 
points (N=4 per group). Results are presented as means ± SEM. A Student’s t-test was used 
to compare Brg1/Brm double-mutant hearts to controls (*, p < 0.05; **, p < 0.01).
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Fig. 2. 
Ultrastructural analysis of Brg1/Brm double-mutant hearts by transmission electron 
microscopy (TEM). A. Representative TEM images of double-mutant hearts at day 14 (post-
tamoxifen induction) with B. degenerating mitochondria (white arrows) and autophagic 
vesicles (blue arrows) indicated. C. Representative TEM images of control hearts at day 14 
(post-tamoxifen induction), which lack evidence of autophagy.
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Fig. 3. 
Brg1/Brm double-mutant hearts have significantly increased autophagic flux. A. Top, 
representative western blot of LC3B isoforms in heart tissue from bafilomycin-treated 
double-mutant and control mice at day 15 post-tamoxifen induction. Bottom, quantification 
of the LC3BII/LC3BI ratio based on densitometry of above immunoblot. B. Representative 
western blot of Beclin in same heart samples from panel (C) with Tubulin serving as a 
loading control. C. RT-qPCR analysis of autophagy genes at day 15 post-tamoxifen 
induction. Data are normalized to Gapdh and represent means ± SEM based on 5 
independent experiments run in duplicate with significant differences indicated (*, p < 0.01). 
D. Quantitative ChIP assays demonstrating BRG1/BRM occupancy at the Bnip3 promoter in 
wild-type mouse heart tissues. As a negative control, the same heart tissues were 
immunoprecipitated with IgG and processed identically. Histograms show the relative 
enrichment by comparing each ChIP sample to input by qPCR (means ± SEM for three 
independent samples).
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Fig. 4. 
Altered mitochondrial dynamics in Brg1/Brm double-mutant hearts. A. Representative TEM 
images of double-mutant and control heart sections. B. Quantification of mitochondrial area 
and size based on measurements from TEM images. Data were obtained from 3 control mice 
and 3 double-mutant mice with >6 fields from each animal. A total of 1,529 control 
mitochondria and 2,380 double-mutant mitochondrial were scored. C. Average mitochondria 
area and number ± SEM based on data from panel (B). (*, p < 0.05).
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Fig. 5. 
Quantitative analysis of mitochondrial number and fusion and fission genes. A. qPCR of 3 
mitochondria-encoded loci normalized to nuclear H19 locus in control and double-mutant 
hearts at day 14 post-tamoxifen induction. Data are presented as means ± SEM based on 5 
independent experiments with significant differences indicated (*, p < 0.01). B. RT qPCR 
analysis of Mfn1 and Opa1 fusion genes normalized to BestKeeper Index in control and 
double-mutant hearts at day 15 post-tamoxifen. Data are presented as means ± SEM based 
on 5 independent experiments with significant differences indicated (*, p < 0.01). C. RT 
qPCR analysis of Fis1 and Drp1 fission genes normalized to BestKeeper Index in control 
and double-mutant hearts at day 15 post-tamoxifen induction. Data are presented as means ± 
SEM based on 5 independent experiments with significant differences indicated (*, p < 
0.01).
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Fig. 6. 
Brg1/Brm double-mutant hearts have increased protein aggregation by quantitative analysis 
of aggregated (amyloid) protein and Pre-Amyloid Oligomers (PAO) recognized by the A11 
antibody. A. Quantification of unfolded protein accumulation in control and double-mutant 
hearts at two time points (days 9 and 15 post-tamoxifen induction). Data represent 5 animals 
per group with significant differences indicated (*, p < 0.01). B. Quantification of pre-
amyloid oligomers in control and double-mutant hearts at day 15 post-tamoxifen induction. 
Five Brg1/Brm double-mutant hearts and three control hearts run in triplicate are 
represented. n.s., not significant. Representative IHC image of GRP78 staining in control 
and double-mutant hearts are shown at day 15 post-tamoxifen induction. Data are presented 
as means ± SEM.
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Fig. 7. 
Immunohistochemistry and RT-qPCR analysis of the unfolded protein response in Brg1/Brm 
double-mutant hearts. A. Immunohistochemical analysis of GRP78, phospho-eIF2 (p-eIF2), 
and CHOP (GADD153). B. RT-qPCR analysis of genes involved in the unfolded protein 
response normalized to Gapdh in day 15 hearts from control and double-mutant mice. C. 
RT-qPCR analysis of genes involved in the unfolded protein response normalized to Gapdh 
in heart failure tissues from patients with conduction defects and control healthy hearts 
(patients detailed in Fig. 4). Data are presented as means ± SEM based on 5 independent 
experiments with significant differences indicated (*, p < 0.05).
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